<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674297</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 28005</org_study_id>
    <nct_id>NCT00674297</nct_id>
  </id_info>
  <brief_title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients</brief_title>
  <official_title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a drug named Fluvastatin is beneficial and
      safe in reducing the risk of cardiovascular disease and blood clots in patients with
      antiphospholipid antibodies or Antiphospholipid Syndrome (APS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine the effects of fluvastatin on
      pro-thrombotic and pro-inflammatory markers in aPL-positive lupus and non-lupus patients
      (primary endpoint) and to determine the safety of fluvastatin in aPL-positive lupus and
      non-lupus patients (secondary endpoint).

      All eligible patients will sign an IRB-approved consent form during the screening visit and
      give blood for baseline laboratory tests. Within a week of the screening visit, all patients
      will be started on Fluvastatin 40 mg daily for three months. At three months patients will be
      instructed to stop the study medication and they will be followed for another three months.
      Thus, the total duration of the study is six months: first three months is interventional and
      the last three months is observational.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarkers: IL6 (pg/mL), IL1β (pg/mL), IL8 (pg/mL), VEGF (pg/mL), TNFα (pg/mL), IFNα (pg/mL), IP10 (pg/mL), sCD40L (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarker sTF (pM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarkers sICAM-1 (ng/mL), sVCAM-1 (ng/mL), sE-sel (ng/mL)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Fluvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will take Fluvastatin 40 mg daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin</intervention_name>
    <description>Fluvastatin 40 mg daily for 3 months</description>
    <arm_group_label>Fluvastatin</arm_group_label>
    <other_name>Lescol, Lescol XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistently antiphospholipid-antibody positive patients (positive lupus anticoagulant
             test, anticardiolipin antibody ≥ 40 GPL /MPL, and/or anti- β2-glycoprotein I antibody
             &gt; 20 SGU/SMU) with or without systemic lupus erythematosus

        Exclusion Criteria:

          -  Younger than 18 year-old

          -  Pregnant

          -  Planning to get pregnant within the next 6 months

          -  Taking other cholesterol lowering agents

          -  Taking other immunosuppressive medications (such as methotrexate, azathioprine,
             cellcept, enbrel, remicade, or rituximab)(Hydroxychloroquine [Plaquenil] during the
             study period is allowed).

          -  Treatment with biologic agents including anti-TNF medications and Rituximab

          -  Treatment with erythromycin, itraconazole, or clarithromycin

          -  Taking prednisone higher than 10 mg daily

          -  Taking non-steroidal anti-inflammatory drug (such as Motrin, Advil, etc) regularly

          -  Have a muscle or liver disease

          -  Have chronic renal disease requiring dialysis

          -  Have hepatitis C and/or HIV infection

          -  Have active infections requiring antibiotics

          -  Have the diagnosis of a systemic autoimmune disease (such as rheumatoid arthritis or
             systemic sclerosis) other than lupus

          -  Have diagnosis of another chronic condition requiring corticosteroid treatment more
             than 10mg daily

          -  History of an allergic reaction to cholesterol lowering agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doruk Erkan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Pierangeli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23933625</url>
    <description>A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients</description>
  </link>
  <reference>
    <citation>Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limón P, Carrera AL, Papalardo E, Martínez-Martínez LA, González EB, Pierangeli SS. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014 Jun;73(6):1176-80. doi: 10.1136/annrheumdis-2013-203622. Epub 2013 Aug 9.</citation>
    <PMID>23933625</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>April 21, 2017</results_first_submitted>
  <results_first_submitted_qc>March 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2018</results_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistently Antiphospholipid Antibody Positive Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>4 groups were recruited: primary antiphospholipid syndrome(PAPS); systemic lupus erythematosus (SLE) with antiphospholipid syndrome(APS)(SLE/APS); persistent aPL positivity without SLE/APS(Primary aPL); and persistent aPL positivity with SLE but no APS(SLE/ aPL). The frequency-matched control group was identified from a databank of healthy persons.</recruitment_details>
      <pre_assignment_details>SLE was defined based on the American College of Rheumatology classification criteria. APS was defined based on the updated Sapporo classification criteria.
Positive aPL was defined as persistently (at least 12 weeks apart) positive LA test, aCL≥40 GPL/MPL and/or aβ2GPI≥20 SGU/SMU.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PAPS</title>
          <description>Primary APS</description>
        </group>
        <group group_id="P2">
          <title>SLE/APS</title>
          <description>SLE with APS</description>
        </group>
        <group group_id="P3">
          <title>Primary aPL</title>
          <description>Persistant aPL positivity without SLE or APS.</description>
        </group>
        <group group_id="P4">
          <title>SLE/aPL</title>
          <description>Persistent aPL positivity with SLE but no APS.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluvastatin</title>
          <description>All patients will take Fluvastatin 40 mg daily for 3 months.
Fluvastatin: Fluvastatin 40 mg daily for 3 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Ages between 18 and 65</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</title>
        <description>Biomarkers: IL6 (pg/mL), IL1β (pg/mL), IL8 (pg/mL), VEGF (pg/mL), TNFα (pg/mL), IFNα (pg/mL), IP10 (pg/mL), sCD40L (pg/mL)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAPS</title>
            <description>Primary APS</description>
          </group>
          <group group_id="O2">
            <title>SLE/APS</title>
            <description>SLE with APS</description>
          </group>
          <group group_id="O3">
            <title>Primary aPL</title>
            <description>Persistant aPL positivity without SLE or APS.</description>
          </group>
          <group group_id="O4">
            <title>SLE/aPL</title>
            <description>Persistent aPL positivity with SLE but no APS.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</title>
          <description>Biomarkers: IL6 (pg/mL), IL1β (pg/mL), IL8 (pg/mL), VEGF (pg/mL), TNFα (pg/mL), IFNα (pg/mL), IP10 (pg/mL), sCD40L (pg/mL)</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Biomarker IL6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" spread="48.4"/>
                    <measurement group_id="O2" value="12.2" spread="103.5"/>
                    <measurement group_id="O3" value="0.4" spread="0.7"/>
                    <measurement group_id="O4" value="2.7" spread="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biomarker IL1B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="7.7"/>
                    <measurement group_id="O2" value="11.4" spread="20.1"/>
                    <measurement group_id="O3" value="0.3" spread="0.6"/>
                    <measurement group_id="O4" value="0.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biomarker IL8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="48.4"/>
                    <measurement group_id="O2" value="27.4" spread="53.7"/>
                    <measurement group_id="O3" value="7.2" spread="50.4"/>
                    <measurement group_id="O4" value="21.6" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biomarker VEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.2" spread="399.6"/>
                    <measurement group_id="O2" value="109.1" spread="348.4"/>
                    <measurement group_id="O3" value="74.6" spread="158.3"/>
                    <measurement group_id="O4" value="67.2" spread="499.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biomarker TNFa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="50.5"/>
                    <measurement group_id="O2" value="11.6" spread="24.1"/>
                    <measurement group_id="O3" value="8.9" spread="15.7"/>
                    <measurement group_id="O4" value="53.9" spread="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biomarker IFNa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="88.4"/>
                    <measurement group_id="O2" value="0.3" spread="367.1"/>
                    <measurement group_id="O3" value="0.3" spread="512.2"/>
                    <measurement group_id="O4" value="13.2" spread="558.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biomarker IP10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427.2" spread="569.8"/>
                    <measurement group_id="O2" value="656.2" spread="454.8"/>
                    <measurement group_id="O3" value="249.7" spread="698.9"/>
                    <measurement group_id="O4" value="472.5" spread="690.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biomarker sCD40L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.5" spread="676.0"/>
                    <measurement group_id="O2" value="145.6" spread="5159.8"/>
                    <measurement group_id="O3" value="149.7" spread="17035.6"/>
                    <measurement group_id="O4" value="76.9" spread="970.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</title>
        <description>Biomarker sTF (pM)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAPS</title>
            <description>Primary APS</description>
          </group>
          <group group_id="O2">
            <title>SLE/APS</title>
            <description>SLE with APS</description>
          </group>
          <group group_id="O3">
            <title>Primary aPL</title>
            <description>Persistant aPL positivity without SLE or APS.</description>
          </group>
          <group group_id="O4">
            <title>SLE/aPL</title>
            <description>Persistent aPL positivity with SLE but no APS.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</title>
          <description>Biomarker sTF (pM)</description>
          <units>pM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.6" spread="381.0"/>
                    <measurement group_id="O2" value="329.2" spread="447.0"/>
                    <measurement group_id="O3" value="190.4" spread="139.0"/>
                    <measurement group_id="O4" value="102.1" spread="177.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</title>
        <description>Biomarkers sICAM-1 (ng/mL), sVCAM-1 (ng/mL), sE-sel (ng/mL)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PAPS</title>
            <description>Primary APS</description>
          </group>
          <group group_id="O2">
            <title>SLE/APS</title>
            <description>SLE with APS</description>
          </group>
          <group group_id="O3">
            <title>Primary aPL</title>
            <description>Persistant aPL positivity without SLE or APS.</description>
          </group>
          <group group_id="O4">
            <title>SLE/aPL</title>
            <description>Persistent aPL positivity with SLE but no APS.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients</title>
          <description>Biomarkers sICAM-1 (ng/mL), sVCAM-1 (ng/mL), sE-sel (ng/mL)</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sICAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.6" spread="406.8"/>
                    <measurement group_id="O2" value="55.1" spread="70.3"/>
                    <measurement group_id="O3" value="163.5" spread="341.7"/>
                    <measurement group_id="O4" value="2.8" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sVCAM-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1128.4" spread="1152.8"/>
                    <measurement group_id="O2" value="156.4" spread="19.3"/>
                    <measurement group_id="O3" value="321.3" spread="1015.1"/>
                    <measurement group_id="O4" value="41.1" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sE-sel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="36.7"/>
                    <measurement group_id="O2" value="14.7" spread="20.4"/>
                    <measurement group_id="O3" value="10.9" spread="26.4"/>
                    <measurement group_id="O4" value="4.1" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>An adverse event (AE) was defined as any untoward medical occurrence in a study patient regardless of causality assessment. A serious AE was defined as one occurring at any dose that met one or more of the following criteria: death; life-threatening; requiring or prolonging inpatient hospitalisation; disabling; or resulting in a congenital anomaly/birth defect.</desc>
      <group_list>
        <group group_id="E1">
          <title>aPL Positive Patients</title>
          <description>Patients with aPL positivity</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Myalgia with high CPK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Myalgia with normal CPK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Doruk Erkan, MD</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>212 774-2291</phone>
      <email>erkand@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

